Company: SYRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023235
Chunk: 79

Company: Syra Health Corp
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 2
Chunk 79
---
You
should read the following discussion and analysis of our financial condition and results of operations together with our unaudited interim
condensed financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical
information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our
actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include,
but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in this
Quarterly Report on Form 10-Q, as may be amended, supplemented or superseded from time to time by other reports we file with the SEC.
All amounts in this report are in U.S. dollars, unless otherwise noted.

Throughout
this Quarterly Report on Form 10-Q, references to “we,” “our,” “us,” the “Company,” or
“Syra,” refer to Syra Health Corp.

Overview

We
are a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all
patient demographics. We leverage deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric
solutions for the betterment of patient lives and health outcome linked to developing a healthier population. We are developing comprehensive
end-to-end solutions in population health, behavioral and mental health, and healthcare workforce. During the current quarter, we reclassified
our digital health and health education revenues into our population health division.

On
October 18, 2024, we received a Notice from Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for its Class
A common stock, for the last 30 consecutive business days for the last thirty consecutive business days, had closed below the minimum
$1.00 per share and, as a result, the Company was not in compliance with the $1.00 minimum bid price requirement (the “Minimum
Bid Price Requirement”) for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).

On
April 11, 2025, we voluntarily delisted our Class A common stock from the Nasdaq Capital Market.

On
June 13, 2025, the Board of Directors of Syra Health Corp. (the “Company”) approved the termination for cause of the employment
agreement between Deepika Vuppalanchi, the Company’s CEO, and the Company dated